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Communicated by Dominque Stoppa-Lyonnet 
 
ABSTRACT: In 5-10% of patients, neurofibromatosis type 1 (NF1) results from microdeletions that 
encompass the entire NF1 gene and a variable number of flanking genes. Two recurrent 
microdeletion types are found in most cases, with microdeletion breakpoints located in paralogous 
regions flanking NF1 (proximal NF1-REP-a and distal NF1-REP–c for the 1.4 Mb type-1 
microdeletion, and SUZ12 and SUZ12P for the 1.2 Mb type-2 microdeletion). A more severe 
phenotype is usually associated with NF1 microdeletion patients than in those with intragenic 
mutations. We characterized NF1 microdeletions in 70 unrelated NF1 microdeleted patients using a 
high-resolution NF1 custom array comparative genomic hybridization (CGH). Genotype-
phenotype correlations were studied in 58 of these microdeletion patients and compared to 389 
patients with intragenic truncating NF1 mutations and phenotyped in the same standardized way. 
Our results confirmed in an unbiased manner the existence of a contiguous gene syndrome with a 
significantly higher incidence of learning disabilities and facial dysmorphism in microdeleted 
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patients compared to patients with intragenic NF1 mutations. Microdeleted NF1 patients also 
showed a trend toward significance for childhood overgrowth. High-resolution array-CGH 
identified a new recurrent ~1.0 Mb microdeletion type, designated as type-3, with breakpoints in 
the paralogous regions middle NF1-REP-b and distal NF1-REP–c. ©2010 Wiley-Liss, Inc. 
KEY WORDS: Genotype-phenotype correlation; High-resolution custom CGH; Neurofibromatosis type 1; NF1 locus 
microdeletion; Standardized phenotype questionnaire; Type-3 NF1 microdeletion  
 
INTRODUCTION 
Neurofibromatosis type 1 (NF1; MIM# 162200) is an autosomal disorder with an estimated incidence of 1 in 
3500 live births (Carey et al., 1986). NF1 is due to autosomal dominant loss-of-function mutations of the NF1 gene 
(neurofibromin 1; NM_000267), a tumour suppressor gene located at 17q11.2 and containing 60 translated exons 
distributed over ~300 kb. In 5-10% of patients, NF1 is caused by genomic microdeletions that encompass the 
entire NF1 gene and a variable number of immediately flanking genes (Kluwe et al., 2004). The majority of such 
NF1 patients have one of two recurrent types: type-1 and type-2 microdeletions. The typical type-1 microdeletion 
is 1.4 Mb long, contains NF1 and at least 14 additional protein-coding genes, four pseudogenes and two 
microRNAs (Supp. Figure S1) and is caused by non-allelic homologous recombination (NAHR) between 
paralogous sequences flanking the NF1 gene: the NF1 proximal and distal low-copy repeats (LCRs): NF1-REP-a 
and NF1-REP-c (Dorchner et al., 2000; López Correa et al., 2000; Jenne et al., 2001, 2003; Forbes et al., 2004; 
Raedt et al., 2006). The typical type-2 microdeletion is smaller (1.2 Mb) and has breakpoints located in the SUZ12 
gene (suppressor of zeste 12 homolog; NM_015355) and its pseudogene SUZ12P (Petek et al., 2003; Kehrer-
Sawatzki et al., 2004; Steinmann et al., 2007; Roehl et al., 2010). Even less frequent, atypical NF1 microdeletions 
with non-recurring breakpoints have also been reported (Riva et al., 2000; Kehrer-Sawatzki et al., 2003, 2008; 
Venturin et al., 2004a; Mantripragada et al., 2006; Pasmant et al., 2008). 
The main features of NF1 include multiple café-au-lait (CAL) spots, skin-fold  freckling, Lisch nodules, and 
benign peripheral nerve sheath tumours (dermal and plexiform neurofibromas) whose occurrence, number, and 
size vary greatly from one patient to another, even from within the same NF1 family (Friedman, 1999). More than 
half of NF1 patients will also develop plexiform neurofibromas, of which about 5-10% will progress into a 
malignant peripheral nerve sheath tumour (MPNST) (Evans et al., 2002). 
While NF1 represents a simply determined Mendelian disorder with complete penetrance, it is however 
characterized by highly variable expressivity in both the number of major features and the occurrence of 
complications (Friedman, 1999; Sabbagh et al., 2009). A more severe clinical phenotype has been reported in NF1 
patients carrying genomic microdeletions that involve the entire NF1 gene, compare to patients with intragenic 
NF1 mutations. This contiguous gene syndrome does appear to include dysmorphic features (Upadhyaya et al., 
1998; López Correa et al., 1999, 2000; Streubel et al., 1999; Riva et al., 2000; Castle et al., 2003; Venturin et al., 
2004b), learning disabilities (Tonsgard et al., 1997; Upadhyaya et al., 1998; Korf et al., 1999; López Correa et al., 
1999, 2000; Streubel et al., 1999; Riva et al., 2000; Castle et al., 2003; Descheemaeker et al., 2004; Venturin et al., 
2004b), cardiovascular malformations (Riva et al., 2000; Venturin et al., 2004b, 2005; Mensink et al., 2006), 
childhood overgrowth (Spiegel et al., 2005), a higher tumour burden and earlier onset of benign neurofibromas 
(Leppig et al., 1997; López Correa et al., 2000; Castle et al., 2003), and probably, a higher incidence of MPNSTs 
(De Raedt et al., 2003) and other malignancies (López Correa et al., 2000). While many reports of NF1 
microdeleted patients (currently > 150 cases) (Mensink et al., 2006) have been published since the initial study in 
1992 (Kayes et al., 1992), to date, little is known about this genotype-phenotype correlation. The limited number 
of microdeletions characterized per study, the imprecise definition of their boundaries, and the lack of appropriate 
control patients, had made it difficult to establish reliable genotype-phenotype correlations. 
To further explore the different NF1 locus rearrangements, and the putative association with such a contiguous 
gene syndrome phenotype, a large cohort of 70 unrelated NF1 microdeleted patients was studied. Their 
microdeletions were accurately characterized using a high-resolution NF1 custom array comparative genomic 
hybridization (CGH) targeting the 17q11.2 region. The genotype-phenotype correlation in 58 of these 
microdeletion patients was statistically evaluated, taking 389 unrelated patients with intragenic NF1 truncating 
mutations as a reference group. All NF1 patients were clinically assessed utilising the same standardized 
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questionnaire collection protocol. Our results demonstrate that NF1 microdeletion patients have a significantly 
higher incidence of learning disabilities and facial dysmorphism than patients with intragenic NF1 mutation, after 
adjusting for age and sex. 
MATERIAL AND METHODS 
Study samples 
A initial panel of 21 NF1 microdeleted patients was identified through a comprehensive mutation screening of 
561 NF1 index cases, enrolled between 2002 and 2005 in the French Clinical Research Program entitled “Study of 
expressivity of neurofibromatosis 1: constitution of a phenotype-genotype database” (coordinator: Pr. P. 
Wolkenstein, Henri Mondor Hospital, Créteil, France) to constitute the so-called ‘NF-France database’, as 
previously described (Sabbagh et al. 2008). The mutation screening of the NF1 gene was performed using a variety 
of NF1 gene screening methodologies that included, DNA and RNA sequencing, for small lesions, polymorphic 
microsatellite marker analysis and multiplex ligation-dependent probe amplification (MLPA) or real-time PCR-
based gene-dosage analysis to permit microdeletion assessment, as previously described (Pasmant et al., 2008; 
Upadhyaya et al., 2008). Among the 561 NF1 index cases, 512 individuals presented a NF1 alteration, 2 showed a 
SPRED1 (sprouty-related, EVH1 domain containing 1; NM_152594) mutation, and no NF1 and SPRED1 mutation 
was identified in the 47 remaining patients, as previously described (Pasmant et al., 2009b). Among the 512 index 
cases with a fully characterized NF1 mutation, 21 patients (4%) presented a NF1 microdeletion, in accordance with 
previous data (Kluwe et al., 2004). A second cohort of 49 NF1 microdeleted patients was selected from routine 
NF1 genotyping at Beaujon Hospital (Clichy, France) and at Institute of Medical Genetics (Cardiff, UK).  
In total, 70 unrelated NF1 patients harbouring a NF1 microdeletion were included in this present study, of 
which 50 patients (79%) had a de novo microdeletion and 13 patients (21%) had inherited their microdeletion. 
Relevant inheritance data was unavailable for the remaining 7 patients. 
The reference control group for this genotype-phenotype correlation study involved the use of non-deleted NF1 
patients with characterized NF1 intragenic truncating mutations selected from the NF-France database. Only 
patients with constitutional NF1 nonsense or frameshift mutations were included as it is assumed all such 
mutations would lead to the premature truncation of neurofibromin. A total of 389 NF1 patients met this criterion 
and were included in the reference group of non-deleted patients. Patients with missense mutations, in-frame 
deletions or insertions were excluded from analyses since the functional consequences of such mutations are 
difficult to assess without functional studies. The 389 patients NF1 molecular alterations were characterized in the 
same laboratory (Beaujon Hospital, Clichy, France). 
For the 70 microdeleted and 389 non-deleted NF1 patients, the full clinical available information was recorded 
utilising a standardized questionnaire. All patients included in this study fulfilled the National Institutes of Health 
(NIH) diagnostic criteria for NF1 (Ferner et al., 2007) and their written informed consent was obtained. 
Phenotypes 
Fourteen major clinical features of NF1 were selected for consideration for the genotype-phenotype association 
study, as previously described (Sabbagh et al., 2008). Four were quantitative traits: number of CAL spots (a 
continuous variable), number of plexiform neurofibromas (a continuous variable), and number of cutaneous and 
subcutaneous neurofibromas (each classified into one of four semi quantitative categories based on the number of 
neurofibromas: 0, 1–9, 10–99 and ≥ 100). The other ten clinical features were coded as binary variables: 
presence/absence of skin-fold freckling, blue-red macules, Lisch nodules, macrocephaly, childhood overgrowth, 
facial dysmorphism, scoliosis, learning disabilities, optic gliomas, and MPNST development. Patients with missing 
data for a particular feature were coded as “unknown”, and were not then considered in models involving that 
feature. Most features were identified by physical examination, with Lisch nodules being diagnosed, or excluded, 
by slit-lamp examination; individuals not given a slit lamp examination were coded as “unknown”. The presence 
or absence of optic gliomas was determined by cranial MRI or CT examination with individuals not given cranial 
imaging being coded as “unknown”. Childhood overgrowth was evaluated only in NF1 patients under the age of 
18 and was defined as height and/or head circumference at least two standard deviations above the age- and sex-
matched population mean. A facial dysmorphism was diagnosed if two or more of the following signs were 
observed: coarse face, flat occiput/brachycephaly, facial asymmetry, prominent forehead, frontal bossing, ptosis, 
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downslanting deep set eyes, eversion of the lateral eyelid, epicanthic folds, high and broad nasal bridge, bulbous 
nasal tip, large and low set ears, malar hypoplasia, wide and prominent philtrum, micrognathia, small pointed chin 
and low posterior hairline. For scoliosis, only scoliotic curves of >10° were taken into account in our analysis. The 
diagnosis of learning disabilities was performed on specific testing of cognitive abilities and/or history of scholar 
difficulties leading to repeating at least one level. Learning deficits most frequently involved visual spatial, visual 
motor integration skills and language-based skills. The prevalence of many other clinical abnormalities (epilepsy, 
hydrocephalus, medullary compression by neurofibroma, cerebrovascular complications, renal artery stenosis, 
pseudoarthrosis, congenital pseudarthrosis of the tibia, dysplastic vertebrae, sphenoid wing dysplasia, 
xanthogranuloma) were too low (≤ 5%) for meaningful statistical analysis.  
The 70 microdeletion and the 389 control patients’ phenotypes, collected through a standardized NF1 
questionnaire have been deposited in NCBI's Gene Expression Omnibus (GEO) (Edgar et al., 2002) and are 
accessible through GEO accession number GSE19730 (at: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19730). 
Characterization of NF1 microdeletions  
The 70 NF1 patients’ microdeletions were accurately characterized by using a custom high-resolution 
oligonucleotide array-CGH targeting the 17q11.2 region. The theoretical (design) and practical aspects (procedure) 
of this custom array-CGH are described in detail elsewhere (Pasmant et al., 2009a). Briefly, we designed a specific 
array-CGH for the NF1 gene and its flanking regions by using the custom Agilent Human Genome 15K 
Microarray (Agilent Technologies, Santa Clara, CA, USA). The array comprised a total of 14,207 oligonucleotide 
probes spanning the whole of chromosome 17, including 12 314 probes spanning a ~8 Mb interval surrounding the 
NF1 locus (~300 kb). This 8-Mb interval spanned the NF1 gene region and included the largest NF1 atypical 
microdeletions described in the literature (Riva P et al., 2000; Kehrer-Sawatzki et al., 2003; Venturin et al., 2004a; 
Pasmant et al., 2008). Details of the microarray design, including the 14,207 oligonucleotide probe chromosome 
locations, has been deposited in NCBI's GEO (Edgar et al., 2002) and are accessible through the GEO accession 
number GSE19730. 
Statistical Analysis 
Multiple logistic regression was performed to test the association of each clinical feature individually with the 
type of constitutional NF1 mutation (microdeletion vs. intragenic mutation). Each regression model had the 
covariates of sex and age at examination (as a continuous variable) to control for potential confounding. Odds 
ratios (OR) and 95% confidence intervals (CI) were also calculated when appropriate. We applied the Bonferroni 
correction, by which the nominal alpha value is adjusted based upon the number of tests performed, to account for 
multiple testing. All statistical analyses were performed with StatView 5.0 software (Cary, NC). 
RESULTS 
Array-CGH characterization of the 70 NF1 microdeletions 
All 70 NF1 microdeletions were accurately characterized with our NF1 customised array-CGH platform and 
consisted of 77% type-1 (54/70), 9% type-2 (6/70), 4% type-3 (new recurrent type) (3/70), and 10% atypical 
microdeletions (7/70) (Table 1). An estimation of the length of each microdeletion as well as their gene content, 
was obtained by using the know locations of the last proximal and first distal non-deleted probes (Table 1; Supp. 
Table S1). A new recurrent ~1.0 Mb microdeletion type, designated here as type-3 microdeletion, was identified in 
three unrelated NF1 patients (GUE, OLI, and N2603), involving NF1-REP-b (but not NF1-REP-a) and NF1-REP-
c. Figure 1 shows the relevant array-CGH profiles for the three recurrent types. The 14,207 array-CGH log2 
normalized ratio data of the 70 patients discussed in this publication have been deposited in NCBI's GEO (Edgar et 
al., 2002) and are accessible through GEO accession number GSE19730 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19730). 
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Table 1. Distribution of NF1 microdeletions types in the 70 studied patients. 
 
Length Number of deleted genes 
(not including NF1) 
Inheritance 
54 type-1 (77%) 1.4 Mb 14 de novo: 85% (40/47) 
inherited: 15% (7/47) 
6 type-2 (9%) 1.2 Mb 13 de novo: 67% (4/6) 
inherited: 33% (2/6) 
3 type-3 (4%) 1.0 Mb 8 de novo: 100% (3/3) 
7 atypical (10%) 
NF00028 
NF00234 
NF00398 
NF00358 
DIE 
N806 
DUB 
 
830 kb 
870 kb 
1.0 Mb 
1.2 Mb 
1.2 Mb 
5.5 Mb 
7.6 MB 
 
10 
6 
9 
15 
10 
~50 
~100 
 
inherited 
de novo 
inherited 
inherited 
inherited 
de novo 
de novo 
 
 
 
Figure 1. Array-CGH profiles of the three types of recurrent (typical) deletions (including type-1, type-2, and the new type-3) 
and NF1 locus schematic representation. 
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Genotype-phenotype correlations 
From the 70 microdeleted NF1 patients, 12 individuals were excluded from the statistical analysis of genotype-
phenotype correlations: two had the largest atypical microdeletions (DUB: 7.6 Mb and N806: 5.5 Mb), and 10 
patients had incomplete phenotype data. In the 58 remaining patients (27 men [46%] and 31 women [53%], mean 
age at examination = 20.5 ± 17.6 years), there were 44 type-1, 6 type-2, 3 type-3, and 5 atypical microdeletions. 
The reference group of non-deleted NF1 patients with intragenic truncating mutations (n=389) consisted of 169 
men (43%) and 220 women (57%) with a mean age at examination of 33.2 ± 13.9 years. 
The clinical characteristics associated with the non-deleted, the microdeleted, and the only type-1 microdeleted 
NF1 patients, are provided in Table 2. 
Table 2. Non-deleted and microdeleted NF1 patients clinical characteristics comparison. 
Clinical features 
NF1 non-
deleted 
patients 
(n=389)a 
All NF1 
microdeleted 
patients (n=58) 
Pb, c 
NF1 type-1 
microdeleted 
patients (n=44) 
Pb, d 
Cutaneous 
neurofibromas   NS  NS 
0 22.1% 49.0%  51.3%  
1-9 20.1% 17.6%  15.4%  
10-99 34.4% 17.6%  17.9%  
≥100 23.4% 15.7%  15.4%  
Subcutaneous 
neurofibromas   NS  NS 
0 41.8% 54.4%  58.1%  
1-9 40.5% 38.6%  37.2%  
10-99 15.2% 5.3%  2.3%  
≥100 2.6% 1.8%  2.3%  
Plexiform 
neurofibromase 0.7 ± 1.0 0.6 ± 1.1 NS 0.6 ± 1.1 NS 
CAL spotse 24.2 ± 16.6 19.3 ± 13.4 NS 20.8 ± 14.5 NS 
Skin-fold freckling 92.0% 87.7% NS 86.4% NS 
Blue-red macules 16.2% 4.0% NS 2.4% NS 
Lisch nodules 64.2% 43.2% NS 40.0% NS 
Macrocephaly 13.1% 20.6% NS 11.5% NS 
Childhood overgrowthf 6.3% 30.4% 0.005 22.2% NS 
Facial dysmorphism 10.8% 51.9% <0.0001* 54.8% <0.0001* 
Scoliosis 38.3% 31.5% NS 31.0% NS 
Learning disabilities 51.9% 80.0% 0.001* 85.7% 0.0006* 
Optic gliomas 14.9% 16.0% NS 15.0% NS 
MPNSTs 3.1% 5.6% NS 7.1% NS 
NS: non significant. a Patients with intragenic NF1 mutations leading to a truncated protein (nonsense or frameshift mutations). 
b
 P values from multiple logistic regression analyses, using sex and age at examination as covariates. Only P values < 0.05 are 
shown. c P values resulting from the comparison of non-deleted NF1 patients with all NF1 microdeleted patients. d P values 
resulting from the comparison of NF1 non-deleted patients with type-1 NF1 microdeleted patients. e Data are expressed as 
mean ± standard deviation. f Only individuals under the age of 18 were evaluated for this trait (63 NF1 non deleted patients, 23 
NF1 microdeleted patients, 18 NF1 type-1 microdeleted patients). * Significant after Bonferroni correction for multiple testing. 
 
The prevalence of the different clinical features in non-deleted patients is comparable to previously reported 
features for the general NF1 population (Huson and Huges, 1994; Friedman and Birch, 1997; North, 2000). When 
compared to this reference group, the microdeleted patients as a whole (n = 58), had a significantly higher 
incidence of dysmorphic features (52% vs. 11%, P < 0.0001, OR = 5.3 [2.7-10.4]) and learning disabilities (80% 
vs. 52%, P = 0.001, OR = 3.3 [1.6-6.7]) at the Bonferroni-corrected significance threshold of 0.004 (0.05 divided 
by 14 for 14 traits tested individually), after adjusting for age and sex (Table 2). Similar results were obtained 
when only the type-1 microdeleted patients were evaluated (n = 44), with OR = 5.3 [2.5-11.2] and OR = 5.0 [2.0-
12.6] for facial dysmorphism and learning disabilities, respectively. Suggestive evidence for association with 
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childhood overgrowth was observed when the microdeleted patients were considered as a whole, with this 
characteristic found to be overrepresented in microdeleted patients compared to non-deleted cases (30% vs. 6%, P 
= 0.005, OR = 8.3 [1.9-36.4]). This association was however not statistically significant after applying the 
conservative Bonferroni correction for multiple comparisons. No significant associations were observed for any 
other clinical features. The apparently higher incidence of cutaneous neurofibromas in non-deleted patients, as 
compared to microdeleted patients (78% vs. 51%, respectively), is easily explainable by the greater proportion of 
prepubertal children (< 10 years old) in the latter group (36% vs. 6%). The association of this trait with the 
presence of an NF1 microdeletion was indeed not significant (P = 0.57) when the effect of age was properly taken 
into account in the multiple regression analysis by using age as a covariate. 
The proportion of de novo cases (which may contain some cases of mosaicism) was significantly higher in 
microdeleted patients compared to patients with intragenic mutations (79% vs. 43%, Chi Square test, P value < 
0.0001). Therefore, somatic mosaicism has to be taken into account in the evaluation of genotype-phenotype 
correlations as it could explain some of the observed differences between the two groups of patients. However, 
when the nature (inherited or sporadic) of the NF1 mutation was introduced in the multiple regression models as a 
covariate, along with sex and age at examination, the associations of facial dysmorphism and learning disabilities 
with NF1 microdeletions (all pooled together) were still significant (P < 0.0001, OR = 4.8 [2.3-10.0] for facial 
dysmorphism, and P = 0.002, OR = 3.4 [1.5-7.3] for learning disabilities). Significant results were also observed 
when only the type-1 microdeleted patients were considered (P = 0.0001, OR = 4.9 [2.2-11.1] for facial 
dysmorphism, and P = 0.001, OR = 5.6 [2.0-15.7] for learning disabilities). Therefore, the association of facial 
dysmorphism and learning disabilities with NF1 microdeletions is unlikely to result from the presence of unknown 
cases of mosaicism in our group of NF1 patients. 
 
DISCUSSION 
The extreme variability of clinical expression in NF1 makes difficult genotype-phenotype correlation, although 
they are of crucial importance for patients and their families. Hence, solid evidence for the existence of a 
microdeletion syndrome has awaited a comprehensive phenotype and genotype evaluation of a cohort of NF1 
microdeletion subjects ascertained in an unbiased manner and compared with an appropriate reference population 
phenotypically evaluated in the same standardized way as microdeleted patients. 
The 70 newly characterized NF1 microdeletion patients described here, the largest cohort ever reported, with 
the exception of meta-analysis from the published literature (Venturin et al., 2004b), has been both genotyped with 
an ad hoc array-CGH platform, and clinically phenotyped utilising a standardized questionnaire. The 
microdeletion patients were compared to 389 patients with NF1 diagnosed according to the NIH clinical criteria 
and presenting intragenic NF1 truncating mutations. NF1 patients with NF1 missense mutations, with no NF1 
mutations, and with SPRED1 mutations were excluded as the NIH criteria cannot reliably distinguish NF1 from 
NF1-like syndrome caused by SPRED1 mutations (NFLS; MIM# 611431) (Pasmant et al. 2009b; Spurlock et al., 
2009; Messiaen et al., 2009). This selection allowed comparing clinical phenotype consequences of NF1 locus 
microdeletions versus the sole NF1 gene haploinsufficiency (intragenic truncating mutations). 
In contrast to previous molecular or cytogenetic techniques, such as multiplex ligation-dependent probe 
amplification or fluorescence in situ hybridization, our customised array-CGH platform was able to 
unambiguously differentiate and characterize NF1 microdeletion types (De Luca et al., 2007; Pasmant et al., 
2009a). Notably, the high-resolution of the array-CGH has allowed identification of a new recurrent NF1 
microdeletion type, designated as type-3, with breakpoints in the paralogous regions middle NF1-REP-b and distal 
NF1-REP–c (Figure 1). The most common type-1 microdeletion involved two paralogous sequences flanking the 
NF1 gene: NF1 proximal and distal LCR (NF1-REP-a and NF1-REP-c). A middle LCR (namely NF1-REP-b) has 
been previously identified between NF1-REP-a and the NF1 gene (Jenne et al., 2003; Forbes et al., 2004; De 
Raedt et al., 2004, 2006) (Supp. Figure S1). These three LCR blocks (NF1-REP-a, b, and c) belong to a complex 
group of paralogs with three components on 17q11.2 (i.e. in the NF1 microdeletion region: NF1-REP-a, b, and c), 
six at 17q21 (NF1-REP-d, e, f, g, h, and i), one at 17q24 (NF1-REP-j), and another on 19p13 (De Raedt et al., 
2004). Interestingly, a genomic microdeletion caused by NAHR between the NF1-REP-a, and NF1-REP-b repeats 
and which included RNF135 and five other genes, but not the NF1 gene, has been described in an individual with 
an overgrowth syndrome (Douglas et al., 2007). For the first time, we describe a recurrent type-3 microdeletion in 
three unrelated NF1 patients (GUE, OLI, and N2603), with breakpoints located in the paralogous sequences NF1-
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REP-b (located between RNF135 and NF1) and NF1-REP-c (Figure 1), consistent with NAHR between these NF1 
medial and distal LCRs. This type-3 microdeletion is ~1 Mb in size and removed the entire NF1 gene and at least 
eight other genes: OMG, EVI2B, EVI2A, RAB11FIP4, CR17orf79, UTP6, SUZ12, and LRRC37B, but not 
LRRC37B2, CRLF3, ATAD5, CENTA2, and RNF135 (Table 1; Supp. Table S1). It is worth noting that the three 
type-3 NF1 microdeletion patients showed facial dysmorphism. Two of them (GUE and OLI) had subcutaneous 
and plexiform neurofibromas. One of them (GUE) presented learning disabilities while this information was 
unavailable for N2603 and OLI who were 4 and 3 years old at the examination time, respectively. 
The present study confirms in an unbiased manner the existence of a contiguous gene syndrome associated with 
specific clinical signs in NF1 microdeletion patients. Two NF1 clinical features, learning disabilities and facial 
dysmorphism show significant association with NF1 microdeletions, after adjusting for multiple comparisons. 
While this finding is consistent with most previous NF1 microdeletion studies, facial dysmorphism appeared to be 
much less prevalent in the microdeleted patients herein described than previously reported (52% in this study 
versus 78% in a meta-analysis of the published literature on the NF1 microdeletions in 78 patients) (Venturin et 
al., 2004b). It is noteworthy that the concomitant presence of both learning disabilities and facial dysmorphism 
was considerably overrepresented in the NF1 microdeleted patients compared to the non-deleted NF1 cases (45% 
vs. 7%, P < 0.0001, OR = 11.0 [5.6-21.4]). Nevertheless, while patients with large deletions of the NF1 locus do 
have a much greater probability to have learning disabilities and facial dysmorphism, it is still impossible to 
predict the presence of a NF1 microdeletion based solely on these clinical symtoms, as previously claimed 
(Tonsgard et al., 1997). No association between these two clinical features was observed in our group of 
microdeleted patients (P = 0.45, after adjusting for age and sex), suggesting that different genetic factors may be 
involved in the determination of each of these traits. Remarkably, haploinsufficiency of OMG gene, mapping in 
the typical NF1 microdeletion interval, has been proposed to be involved in the learning disabilities found in NF1 
microdeletion patients (Venturin et al., 2006). 
Our study also suggests some evidence of an association of childhood overgrowth with NF1 microdeletion, 
although this was not significant at the Bonferroni-corrected threshold. This observation confirms results published 
by Spiegel et al. who proposed that overgrowth was indeed a component of the phenotypic spectrum of the NF1 
microdeletion syndrome (Spiegel et al., 2005). RNF135 haploinsufficiency was proposed to be responsible for the 
overgrowth often observed in individuals with NF1 microdeletions (Douglas et al., 2007). Interestingly, none of 
the four microdeleted patients with no RNF135 deletion (i.e. RNF135 not included in the microdeletion interval), 
NF00234, and three type-3 microdeletion patients (GUE, OLI, and N2603), presented childhood overgrowth. It is 
also of note that no RNF135 point mutation or deletion has been found in patients with NF1 intragenic truncating 
mutation and with overgrowth, ruling out a putative double heterozygosity for mutations in both the NF1 and 
RNF135 genes in these patients (data not shown). Our cohort of NF1 microdeleted patients had twice as many 
MPNSTs as did the non-deleted patients (6% vs. 3%), in agreement with previous published results (De Raedt et 
al., 2003). This finding is however not significant, because of the lack of power from small sample size and the 
low incidence of this trait. Hence, these two last findings (childhood overgrowth and possibly increased incidence 
of MPNSTs) warrant be replicated in an independent sample before any conclusions can be drawn. 
This study confirms that custom high-resolution array-CGH is a sensitive approach, suitable for accurate 
characterization of NF1 microdeletions and able to unambiguously differentiate between the types of 
microdeletions. Further studies are necessary to identify which gene(s) among the 14 genes deleted in NF1 
microdeletion syndrome, are responsible for learning disabilities and facial dysmorphism. Our study demonstrates 
however that NF1 microdeletion patients present a more severe phenotype than that observed in classical NF1 
patients, particularly in respect to the presence of learning disabilities. These data must now to be taken into 
account in NF1 patients’ follow-up care. 
 
REFERENCES 
Box GEP, Cox DR. An analysis of transformations. J. R. Stat. Soc. B 1964; 26: 211-252. 
Carey JC, Baty BJ, Johnson JP, Morrison T, Skolnick M, Kivlin J. 1986. The genetic aspects of neurofibromatosis. Ann N Y 
Acad Sci 486:45-56. 
Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M. 2003. Evaluation of genotype-phenotype correlations in 
neurofibromatosis type 1. J Med Genet 40:e109. 
Deleted: Running Title
Page 10 of 14
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10  Pasmant et al. 
De Luca A, Bottillo I, Dasdia M C, Morella A, Lanari V, Bernardini L, Divona L, Giustini S, Sinibaldi L, Novelli A, Torrente I, 
Schirinzi A, Dallapiccola B. 2007. Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe 
amplification. J Med Genet 44:800-8. 
De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E. 2003. Elevated 
risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:1288–1292. 
De Raedt T, Brems H, López-Correa C, Vermeesch JR, Marynen P, Legius E. 2004. Genomic organization and evolution of the 
NF1 microdeletion region. Genomics 84:346-60. 
Descheemaeker MJ, Roelandts K, De Raedt T, Brems H, Fryns JP, Legius E. 2004. Intelligence in individuals with a 
neurofibromatosis type 1 microdeletion. Am J Med Genet A 131:325–326. 
Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. 2000. NF1 microdeletion breakpoints are clustered at 
flanking repetitive sequences. Hum Mol Genet 9:35-46. 
Douglas J, Cilliers D, Coleman K, Tatton-Brown K, Barker K, Bernhard B, Burn J, Huson S, Josifova D, Lacombe D, Malik M, 
Mansour S, Reid E, Cormier-Daire V, Cole T; Childhood Overgrowth Collaboration, Rahman N. 2007. Mutations in 
RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nat Genet 
39:963-5. 
Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data 
repository. Nucleic Acids Res 30:207-10. 
Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. 2002. Malignant peripheral nerve sheath tumours in 
neurofibromatosis 1. J Med Genet 39:311-4. 
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. 
2007. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44:81-8. 
Forbes SH, Dorschner MO, Le R, Stephens K. 2004. Genomic context of paralogous recombination hotspots mediating 
recurrent NF1 region microdeletion. Genes Chromosomes Cancer 41:12-25. 
Friedman JM, Birch PH. 1997. Type 1 Neurofibromatosis: a descriptive analysis of the disorder in 1728 patients. Am J Med 
Genet 70:138–43. 
Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6. 
Huson SM, Huges RC. 1994. The neurofibromatosis: a clinical and pathogenetic overview. London: Chapman and Hall, Inc. 
Jenne DE, Tinschert S, Reimann H, Lasinger W, Thiel G, Hameister H, Kehrer-Sawatzki H. 2001. Molecular characterization 
and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J 
Hum Genet 69:516-27. 
Jenne DE, Tinschert S, Dorschner MO, Hameister H, Stephens K, Kehrer-Sawatzki H. 2003. Complete physical map and gene 
content of the human NF1 tumor suppressor region in human and mouse. Genes Chromosomes Cancer 37:111-20. 
Kayes LM, Riccardi VM, Burke W, Bennett RL, Stephens K. 1992. Large de novo DNA deletion in a patient with sporadic 
neurofibromatosis 1, mental retardation, and dysmorphism. J. Med. Genet 29:686–690. 
Kehrer-Sawatzki H, Tinschert S, Jenne DE. 2003. Heterogeneity of breakpoints in non-LCR-mediated large constitutional 
deletions of the 17q11.2 NF1 tumour suppressor region. J Med Genet 40:e116. 
Kehrer-Sawatzki H, Kluwe L, Sandig C, Kohn M, Wimmer K, Krammer U, Peyrl A, Jenne DE, Hansmann I, Mautner VF. 
2004. High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by 
somatic recombination of the JJAZ1 gene. Am J Hum Genet 75:410-423. 
Kehrer-Sawatzki H, Schmid E, Fünsterer C, Kluwe L, Mautner VF. 2008. Absence of cutaneous neurofibromas in an NF1 
patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region. Am J Med Genet A 
146A:691-9. 
Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, Mautner VF. 2004. Screening 500 unselected 
neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111-6. 
Page 11 of 14
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
< Genotype-phenotype correlation in NF1 microdeletion patients > 11 
 
Korf BR, Schneider G, Poussaint TY. 1999. Structural anomalies revealed by neuroimaging studies in the brains of patients 
with neurofibromatosis type 1 and large deletions. Genet Med 1:136–40. 
Leppig KA, Kaplan P, Viskochil D, Weaver M, Ortenberg J, Stephens K. 1997. Familial neurofibromatosis 1 microdeletions: 
cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 73:197-204. 
López Correa C, Brems H, Lázaro C, Estivill X, Clementi M, Mason S, Rutkowski JL, Marynen P, Legius E. 1999. Molecular 
studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Hum Mutat 14:387-93. 
López Correa C, Brems H, Lázaro C, Marynen P, Legius E. 2000. Unequal meiotic crossover: a frequent cause of NF1 
microdeletions. Am J Hum Genet 66:1969-74. 
Mantripragada KK, Thuresson AC, Piotrowski A, Díaz de Ståhl T, Menzel U, Grigelionis G, Ferner RE, Griffiths S, Bolund L, 
Mautner V, Nordling M, Legius E, Vetrie D, Dahl N, Messiaen L, Upadhyaya M, Bruder CE, Dumanski JP. 2006. 
Identification of novel deletion breakpoints bordered by segmental duplications in the NF1 locus using high resolution 
array-CGH. J Med Genet 43: 28-38. 
Mensink KA, Ketterling RP, Flynn HC, Knudson RA, Lindor NM, Heese BA, Spinner RJ, Babovic-Vuksanovic D. 2006. 
Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the 
literature. J Med Genet 43:e8. 
Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, 
Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim 
C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, 
Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E. Clinical and mutational 
spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009;302:2111-8. 
North K. 2000. Neurofibromatosis type 1. Am J Med Genet 97:119–27. 
Pasmant E, de Saint-Trivier A, Laurendeau I, Dieux-Coeslier A, Parfait B, Vidaud M, Vidaud D, Bièche I. 2008. 
Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 
contiguous gene syndrome patient. Eur J Hum Genet 16:1459-66. 
Pasmant E, Sabbagh A, Masliah-Planchon J, Haddad V, Hamel MJ, Laurendeau I, Soulier J, Parfait B, Wolkenstein P, Bièche I, 
Vidaud M, Vidaud D. 2009a. Detection and characterization of NF1 microdeletions by custom high resolution array CGH. J 
Mol Diagn 11:524-9. 
Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-
Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN. 2009b. SPRED1 germline mutations caused 
a neurofibromatosis type 1 overlapping phenotype. J Med Genet. 46:425-30. 
Petek E, Jenne DE, Smolle J, Binder B, Lasinger W, Windpassinger C, Wagner K, Kroisel PM, Kehrer-Sawatzki H. 2003. 
Mitotic recombination mediated by the JJAZF1 (KIAA0160) gene causing somatic mosaicism and a new type of 
constitutional NF1 microdeletion in two children of a mosaic female with only few manifestations. J Med Genet 40:520-5. 
Raedt TD, Stephens M, Heyns I, Brems H, Thijs D, Messiaen L, Stephens K, Lazaro C, Wimmer K, Kehrer-Sawatzki H, 
Vidaud D, Kluwe L, Marynen P, Legius E. 2006. Conservation of hotspots for recombination in low-copy repeats associated 
with the NF1 microdeletion. Nat Genet 38:1419-23. 
Riva P, Corrado L, Natacci F, Castorina P, Wu BL, Schneider GH, Clementi M, Tenconi R, Korf BR, Larizza L. 2000. NF1 
microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J 
Hum Genet 66:100-9. 
Roehl AC, Cooper DN, Kluwe L, Helbrich A, Wimmer K, Hogel J, Mautner VF, Kehrer-Sawatzki H. 2010. Extended runs of 
homozygosity at 17q11.2: an association with type-2 NF1 deletions? Hum Mutat [Epub ahead of print]. 
Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, Combemale P, Ferkal S, Vidaud M, Aubourg P, Vidaud 
D, Wolkenstein P; members of the NF France Network. 2009. Unravelling the genetic basis of variable clinical expression 
in neurofibromatosis 1. Hum Mol Genet 18:2768-78. 
Spiegel M, Oexle K, Horn D, Windt E, Buske A, Albrecht B, Prott EC, Seemanová E, Seidel J, Rosenbaum T, Jenne D, 
Kehrer-Sawatzki H, Tinschert S. 2005. Childhood overgrowth in patients with common NF1 microdeletions. Eur J Hum 
Genet 13:883-8. 
Deleted: Running Title
Page 12 of 14
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12  Pasmant et al. 
Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, Side L, Davies S, Haan E, Kerr B, Huson SM, Upadhyaya M. 
2009. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 
phenotype. J Med Genet. 46:431-7. 
Steinmann K, Cooper DN, Kluwe L, Chuzhanova NA, Senger C, Serra E, Lazaro C, Gilaberte M, Wimmer K, Mautner VF, 
Kehrer-Sawatzki H. 2007. Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous 
recombination hotspots and an apparent preference for female mitotic recombination. Am J Hum Genet 81:1201-20. 
Streubel B, Latta E, Kehrer-Sawatzki H, Hoffmann GF, Fonatsch C, Rehder H. 1999. Somatic mosaicism of a greater than 1.7-
Mb deletion of genomic DNA involving the entire NF1 gene as verified by FISH: further evidence for a contiguous gene 
syndrome in 17q11.2. Am J Med Genet 87:12-6. 
Tonsgard JH, Yelavarthi KK, Cushner S, Short MP, Lindgren V. 1997. Do NF1 gene deletions result in a characteristic 
phenotype? Am J Med Genet 73:80-6. 
Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, Mudd S, Penttinen M, Cordeiro I, Ponder M, Ponder BA, 
Krawczak M, Cooper DN. 1998. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal 
origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet 
102:591-7. 
Upadhyaya M, Spurlock G, Monem B, Thomas N, Friedrich RE, Kluwe L, Mautner V. 2008. Germline and somatic NF1 gene 
mutations in plexiform neurofibromas. Hum Mutat. 29:E103-E111. 
Venturin M, Gervasini C, Orzan F, Bentivegna A, Corrado L, Colapietro P, Friso A, Tenconi R, Upadhyaya M, Larizza L, Riva 
P. 2004a. Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 
microdeletions. Hum Genet 115:69-80. 
Venturin M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M, Hernandez C, Thompson P, Upadhyaya M, Larizza L, 
Riva P. 2004b. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes 
in 17q11.2. J Med Genet 41:35-41. 
Venturin M, Bentivegna A, Moroni R, Larizza L, Riva P. 2005. Evidence by expression analysis of candidate genes for 
congenital heart defects in the NF1 microdeletion interval. Ann Hum Genet 69:508-16. 
Venturin M, Moncini S, Villa V, Russo S, Bonati MT, Larizza L, Riva P. 2006. Mutations and novel polymorphisms in coding 
regions and UTRs of CDK5R1 and OMG genes in patients with non-syndromic mental retardation. Neurogenetics 7:59-66. 
Page 13 of 14
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
< Genotype-phenotype correlation in NF1 microdeletion patients > 13 
 
 
29 000 Kb
29 500 Kb
30 000 Kb
LRRC37B2
SUZ12P*
CRLF3
NF1-REP-a
LOC646013*
ATAD5
C17ofr42
CENTA2
RNF135
DPRXP4*
NF1
OMG
EVI2A
AK3P1*
RAB11FIP4
MIR193A
MIR365-2
CR17orf79
UTP6
SUZ12
LRRC37B
NF1-REP-c
EVI2B
*  : Pseudogene
17p13.3
17p13.2
17p13.1
17p12
17p11.2
17q11.1
17p11.1
17q25.2
17q21.2
17q21.1
17q12
17q11.2
17q25.1
17q23.1
17q22
17q21.31
17q21.33
17q21.32
17q23.2
17q24.3
17q24.2
17q24.1
17q25.3
17q23.3
chr17:1-81,195,210
NF1-REP-b
 
Supp. Figure S1. Schematic representation of the 17q11.2 region. Type-1 1.4 Mb microdeletion encompasses the 
entire 350-kb NF1 gene, 14 flanking protein-coding genes, four pseudogenes, and two microRNAs. 
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Supp. Table S1. Gene content of the three typical microdeletions and the < 2 Mb atypical microdeletions. 
Microdeletion Type-1 Type-2 Type-3 Atypical Atypical Atypical Atypical Atypical Atypical Atypical 
Patient    NF00028 NF00234 NF00398 NF00358 DIE N806 DUB 
Genes 14 13 8 10 6 9 15 10 ~50 ~100 
SLC6A4                             
BLMH                            
TMIGD1                            
CPD                            
GOSR1                            
TBC1D29                            
LRRC37B2                        
CRLF3                       
ATAD5                       
C17orf42                       
CENTA2                       
RNF135                       
NF1                     
OMG                     
EVI2B                     
EVI2A                     
RAB11FIP4        
 
      
 
       
MIR193A                       
MIR365-2             
 
     
 
     
C17orf79                         
UTP6           
 
              
SUZ12    
 
                      
LRRC37B  
 
     
 
                    
RHOT1                          
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